Jump to content

All Activity

This stream auto-updates

  1. Earlier
  2. Things have been going well for us at Kimer Med. Here's the latest: Dengue Fever is a tropical viral disease that infects up to 400 million people every year in parts of Africa, Southeast Asia and Central and South America. According to the CDC, it lacks effective treatments, resulting in about 100 million people developing symptomatic disease and 22,000 deaths from those infections every year. Dengue is transmitted by mosquitos. Getting infected a second time is much more risky than the first time. Dengue is also interesting to us since it has some features in common with SARS-CoV-2
  3. Hi , Greetings from New Zealand! I hope you're doing well. Since my last email about our biotech startup, Kimer Med, we've made tremendous progress. I thought you might be interested in hearing our most recent news: we successfully closed our seed funding round. This will enable us to greatly expand the scope and speed of development of our broad-spectrum antiviral drug. If you're interested in following our work on a regular basis, you can sign-up for our subscriber email list here: https://kimermed.co.nz/landing We also have a discussion forum: https://forum.kimermed.
  4. You have mentioned that you tried to contact Dr. Rider about DRACO, but were unable to reach him. I recently went to Dr. Rider's Rider Institute website and it appears that it is being maintained. Perhaps contacting him is worth another try. https://riderinstitute.org/
  5. @RickI used to work in US pharma research. Funding for CDC approval takes millions of dollars and 9 years on average (7 at best) to prove initial safety and efficacy. Then 90% of drugs get pulled for negative long term data. So given the amount of money needed this is beyond what crowdfunding can provide if you want the USA to approve it (prob at least $10 million needed).
  6. Very interesting! Thanks for the link.
  7. Youtube link: Dolly@20 Symposium - Lissa Herron I thought this was interesting and worth sharing.
  8. Greetings from Kimer Med. We've had a productive week on the science front, including completing four different types of analysis of our antiviral protein, and a fifth is in progress. The results of these tests will be used to help inform our ongoing efforts to improve the fabrication process and product purity. We are currently using E. Coli bacteria to make the protein, although it's possible that will change at some point. Recombinant protein fabrication is a fascinating field! Our fundraising efforts continue. If you'd like to support our work and help us move faster, here's
  9. Greetings from Kimer Med! Our fundraising and science efforts are continuing apace. Nothing new to report at the moment, but I thought I'd send a quick update anyway, to let you know that things are still moving forward. Operating on a shoestring, as we are at the moment, definitely slows us down. If you'd like to support our work and help us move faster, we have a new donation page on our website: https://www.kimermed.co.nz/donate Covid-related news has been interesting lately. Between reports of new strains and vaccine failures of various kinds, it's clear t
  10. I think there are a few DAOs in existence that could supply funding in return for recognition. In fact crypto currency communities as a whole have funded all sorts of things just to be seen as a community that is made up of charitable people. But it does not make much sense to take any money from a research company and put it into a DAO or for a public company to create a DAO to receive charitable funds that are intended to fund the company when people could just donate directly to the company without the additional complication of a DAO. There are cases where it might be a good i
  11. Hi, I hope you had a good holiday and a happy new year. Just a short update this week, since as I mentioned last time, New Zealand pretty much closes down from mid-Dec to mid-Jan for the holidays. Things will finally be coming back to life next week. On the science side, the protein from the second fabrication batch that I mentioned in my last update is now in-hand. As the last step of fabrication, we run the dissolved compound through a 0.2 micron filter, which effectively sterilizes it. After that, it can be safely stored at 4C (in a standard refrigerator). The
  12. Hi, Our crowdfunding campaign is now complete. We raised NZ $24,200 (about USD $17,000). Thanks again to those who donated! We have recently completed fabrication of the second batch of our protein, with significantly improved purity and yield. Excellent progress. We are now working on replicating some of the basic antiviral functionality described in the 2011 paper about DRACO. There is a surprising amount of interesting and complex science involved. We are anticipating that several iterations of fabrication and testing may be required. In case you haven't b
  13. Hi, Our crowdfunding campaign is coming down to its last 48 hours. Thanks if you have already donated. In case you haven't had a chance to check out the campaign recently, here's a link: https://donate.kimermed.co.nz/campaign/2/ending-viral-disease Since the last Weekly Update, there have been a couple of new posts in the members only section of the forum: https://forum.kimermed.co.nz/index.php?/forum/15-general-discussion/ If you made a donation more than about a week ago and don't yet have access to that part of the forum, please let me know (more recent
  14. I caught this story on Oramed which delivers proteins to treat diabetes which are encapsulated and then have increased absorption in the small intesting. Perhaps it might be applicable for VTose. https://jewtube.tv/innovation/israeli-pharmaceutical-developed-the-first-pill-to-treat-diabetes-without-insulin-shots/ https://www.oramed.com/technology/scientific-abstracts/
  15. That's encouraging. A low inflammatory diet will minimize immune cytokine damage. Make GcMAF a recommended contraindication as it increases antibody production. If VTose works you shouldn't need it. ME patient antibody production is suppressed anyway by the viral nagalase so it may not end up being a problem. Critical Covid and Nutrition Information for Patients.pdf
  16. Glad to see a group like this exists. Not long ago last year, I read about DRACO and was wondering why it hadn't yet been looked into. Relieved to see that it is now though! For perks, I like the idea of a keychain, magnet, and/or vinyl decal with the company logo on it. However, maybe it could have the small line inside the virus shape changed to look like a dragon, since DRACO is named after them, like this: I also feel a small plush is a great idea but I am unsure about how automation can/will go with those. Hope this helps!
  17. Rick

    Delivery method

    The molecular weight of VTose is roughly 35 kDa. One of the earliest papers about transduction tags showed effectiveness with a protein with a MW of 120 kDa: In vivo protein transduction: delivery of a biologically active protein into the mouse - PubMed (nih.gov) Transport of even larger proteins is undoubtedly possible.
  18. My biggest concern is the chance that immune response that could give a serious anaphylaxis reaction in up to 30% of patients. Granted, it may not occur with VTose but that's a high number. https://www.cell.com/molecular-therapy-family/molecular-therapy/fulltext/S1525-0016(16)33585-7
  19. What's the molecular weight of the VTose system? What is the largest molecular weight that can be encapsulated into a protein transduction tag? Immune reaction is a major side effect of the injected PTTs. https://www.cell.com/molecular-therapy-family/molecular-therapy/fulltext/S1525-0016(16)33585-7 I'm not sure if this would be a problem with the oral form as well.
  20. If you can't get that patent there is no way to raise the money to afford to complete the drug approval process.
  21. I see the problem. Maybe a port can be put in temporarily for self injection for a year or so and checked monthly by the patient's primary care practitioner. This is a big hurdle. How often does it need to be injected? Your immediate concerns should be reformulating it for caspase 7 and securing a provisional patent.
  22. Specific treatment protocols is one of the things we will be researching. We certainly will also be putting some effort into trying to develop an oral form. However, proteins are very susceptible to damage and degradation by the digestive system, so it's a challenge. Insulin, for example, which is a relatively small peptide (a short protein), still doesn't have an oral form.
  23. Ok, for a 10 year myalgic encephalomyelitis patient who has to clear years of infected cells what are we looking it? # of injections over what time interval? Can an oral form be developed?
  24. For Rider's study with mice to treat Influenza, he only treated them for a few days. Dosing in humans will depend on a number of factors, such as the type of virus being treated, the severity of the infection, whether there are other viral co-infections, and so on. We are also looking at formulation changes that are intended to influence the required dose. The specifics in this area are one of the many things that we plan to determine during clinical trials.
  25. What kind of VTose dosing duration and schedule are we looking at for injections? My concern is that apoptosis is very intense. I have a treatment worked out, Craysing, that appears effective for combined HHV6 and EBV infection which is administered by mouth and that one appears to be taking 9 months. I think the limiting factor is that it relies on antibodies and can only cover so many cells per day so you get a layer by layer removal of infected tissue. However, if we induce the same amount of total apoptosis within an accelerated time frame, say 3 months, then we have do deal with a much
  1. Load more activity
×
×
  • Create New...